Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial
The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...
Outlook Therapeutics Trial of Eye Disease Treatment Misses Key Endpoint
Outlook said it remains confident that ONS-5010, marketed as Lytenava in the EU, is an important therapy for the treatment of wet age-related macular degeneration in place of off-label repackaged ...
FierceBiotech3 天
Outlook's stock plummets after eye drug fails to match Lucentis, but biotech still plans ...
Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...
Outlook plunges as lead asset fails in wet AMD study
Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.
Opthea Highlights Innovative Wet AMD Therapy
Opthea Limited Sponsored ADR (OPT) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
Piper Sandler 36th Annual Healthcare Conference Fireside Chat Date: Tuesday, December 3rd, 2024 Fireside Chat Time: 1:30 PM ET Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO ...
Natural chemical from veg could reduce risk of losing eyesight 30%
A study found people taking the substances found in natural vegetables were 25 to 30% less likely to lose their vision ...
RNA editing is the next frontier in gene therapy—here's what you need to know
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...
modernretina6 天
First patient dosed in phase I/IIa clinical trial of ABI-110
ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.